Neurogene Inc.
Developing genetic medicines using gene therapy for rare and devastating neurological diseases.
NGNE | NDAQ
Overview
Corporate Details
- ISIN(s):
- US64135M1053 (+2 more)
- LEI:
- Country:
- United States of America
- Address:
- 535 W 24TH STREET, 10011 NEW YORK
- Website:
- https://www.neurogene.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Neurogene Inc. is a clinical-stage biotechnology company founded in 2018, focused on developing life-changing genetic medicines for patients and families impacted by rare and devastating neurological diseases. The company utilizes its proprietary EXACT gene therapy technology platform to engineer treatments for complex genetic conditions. Neurogene's development pipeline includes therapeutic candidates for diseases such as Rett syndrome and CLN5 Batten disease. Collaborating with patient communities, advocacy organizations, and medical experts, the company's mission is to translate innovative science into effective therapies for conditions with significant unmet medical needs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Neurogene Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Neurogene Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Neurogene Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
